Non-pharmacological treatments have always been considered important in the management of Chronic Coronary Syndromes. Nutraceuticals ("Nutrition" + "Pharmaceutical") could fall both under the definition of non-pharmacological treatment and pharmacological one or, probably more correctly, in the middle of these two kinds of therapies. However, the word “nutraceuticals” never appears in the latest guidelines on this issue. This is probably determined by the fact that evidences on this topic are scarce and most of the published articles are based on preclinical data while translational experiences are available only for some molecules. In this review we will focus on nutraceutical strategies that act on the ischemic myocardium itself and not only on the cardiovascular risk factors. As demonstrated by the important number of papers published in recent years, this is an evolving topic and evaluated substances principally act on two mechanisms (cardiac energetics and ischemia-reperfusion damage) that will be also reviewed.

Tognola, C., Alessandro, M., Milani, M., Cartella, I., Tavecchia, G., Grasso, E., et al. (2021). Nutraceuticals in Chronic Coronary Syndromes: Preclinical Data and Translational Experiences. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 28(1), 13-25 [10.1007/s40292-020-00416-8].

Nutraceuticals in Chronic Coronary Syndromes: Preclinical Data and Translational Experiences

Grasso E.;Sun J.;Giannattasio C.
2021

Abstract

Non-pharmacological treatments have always been considered important in the management of Chronic Coronary Syndromes. Nutraceuticals ("Nutrition" + "Pharmaceutical") could fall both under the definition of non-pharmacological treatment and pharmacological one or, probably more correctly, in the middle of these two kinds of therapies. However, the word “nutraceuticals” never appears in the latest guidelines on this issue. This is probably determined by the fact that evidences on this topic are scarce and most of the published articles are based on preclinical data while translational experiences are available only for some molecules. In this review we will focus on nutraceutical strategies that act on the ischemic myocardium itself and not only on the cardiovascular risk factors. As demonstrated by the important number of papers published in recent years, this is an evolving topic and evaluated substances principally act on two mechanisms (cardiac energetics and ischemia-reperfusion damage) that will be also reviewed.
Articolo in rivista - Review Essay
Cardiac energetics; Chronic coronary syndromes; Ischemia-reperfusion injury; Nutraceutical;
English
13
25
13
Tognola, C., Alessandro, M., Milani, M., Cartella, I., Tavecchia, G., Grasso, E., et al. (2021). Nutraceuticals in Chronic Coronary Syndromes: Preclinical Data and Translational Experiences. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 28(1), 13-25 [10.1007/s40292-020-00416-8].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/306848
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact